China Grand Pharma and its US affiliate, Sirtex Medical, invested $30 million into OncoSec Medical, a New Jersey immunotherapy company. China Grand Pharma will own 53% of OncoSec after the transaction and China Grand Pharma will have China and Asian rights to OncoSec’s TAVO (tavokinogene telseplasmid), a device that delivers DNA-based interleukin-12 (IL-12) directly into tumors, stimulating an immune response. OncoSec will use the funds to complete two ongoing TAVO clinical trials in combination with Merck‘s Keytruda®, including trials in melanoma and triple-negative breast cancer.
Source: China Biotoday
